


Uscom (UCM) – Global Medical Devices



PhD(med), MPhil(med), FASE, DMU(cardiol)
Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland

Uscom Executive Chairman/CEO

The Measure of Life

Disclaimer

This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs of any individual or organisation.

While Uscom (the "Company") has taken due care in compiling the information, neither the Company nor its officers or advisors or any other person warrants the accuracy, reliability, completeness or timeliness of the information or guarantees the commercial or investment performance of the Company. Certain information may relate to protected intellectual property rights owned by Uscom. By viewing this presentation the viewer accepts the terms of the Company NDA. The information does not constitute advice of any kind and should not be relied on as such. Investors must make their own independent assessment of the Company and undertake such additional enquiries as they deem necessary or appropriate for their own investment purposes. Any and all use of the information is at your own risk.



Uscom

"A rapidly growing Australian medical device company with world leading products and a strategic global corporate vision..."









Uscom Recognition

Company of the Year, 2014
Johnson & Johnson Innovation Industry Excellence Awards

"A milestone driven, rapidly growing global medical device company, with real products, real revenue, real growth and an aggressive growth strategy"

Johnson Johnson Innovation





Business Background

- Premium noninvasive cardiovascular and pulmonary monitoring devices
- Addressing the growing threat of superbugs, heart failure, hypertension and asthma
- Validated, clinically accepted, cost and life saving devices with critical applications
- Aggressive global growth strategy
- IP protected with regulatory approvals
- Uscom BP+ and SpiroSonic for market FY 2017
- +50% growth from USCOM alone, with BP+ and SpiroSonic revenue ahead

Corporate

- ASX listed (UCM)
- Headquartered in Sydney
- Market cap of \$20m
- 100m shares on issue
- Rob Phillips, Founder and CEO, holds 20% of company

Board & Management


- Rob Phillips, Chairman & CEO
- Sheena Jack, Director (HCF, Moneytime Health)
- Christian Bernecker, Director (Stream)
- Nick Schicht, General Manager

Financials

- Sales +59% 2015
- Revenue +48% 2015 (\$2+m)
- Cash consumption \$1m
- Gross Margins ~ 78%
- Cash ~ \$0.8m



Strategic growth



Rapidly strengthening balance sheet
Acquisitive, strategic and diversified entity
Acquired and integrated Pulsecor (2013) and Thor (2015)
Debt free acquisitions — scrip, raising and operations
Scientific, operational and strategic synergy
New product developments funded from operations
Two new product suites ready for revenue/market
UK entity established
Budapest manufacturing profitable
Preparing for volume manufacture of BP+ and SpiroSonic



Products and Market

Multiple high fidelity noninvasive digital medical devices

Fluid, Sepsis & Heart Failure

- US 1.3bn market *
- CAGR of 7.6%*
- CE, FDA, TGA, CFDA

USCOM 1A Cardiac Output Monitoring



Hypertension & Vascular Health

- US 1.7bn market*
- CAGR of 11.5% *
- CE, FDA, TGA

BP+Blood Pressure Monitoring



COPD & Asthma

- US 400m market *
- CAGR of 6.5%*
- CE, TGA, FDA

SpiroSonicPulmonary Monitoring





Products - USCOM 1A

Heart failure, hypertension, sepsis, fluid
Non invasive, accurate, compact, platform technology

Accurate cardiac output

Cardiac stroke volume

Systemic vascular resistance

Left + right heart measurement



Works with all other hospital equipment

Intuitive touch screen

Real time data


Platform technology with multiple uses

Non invasive, real time, beat-to-beat haemodynamics



Products - USCOM 1A

USCOM use in pediatric sepsis



-46% Mortality!



Septic Shock Mortality in King Chulalongkorn Memorial Hospital – Uscom use began in 2013.

Thongnual C, Hantragool S, Samransamriatkit R. Efficacy of non-invasive cardiac monitoring (Ultrasonic Cardiac Output Monitor) guide in management of fluid refractory pediatric septic shock. Pediatric Respiratory and Critical Care Medicine Association, Annual Scientific Meeting. 2016; proceedings.




Products - Uscom BP+



Hypertension, heart failure and vascular disease Central Blood Pressure and Pulse Wave Analysis The new standard for hypertension

- FDA, CE Mark, TGA approvals
- Supra-systolic Oscollometry
- Reliable and
- accurate
- Central and
- Brachial BP
- Replaces sub-systolic methods (cuff)



- Home or clinic
- PPW Analysis
- Results in 30 seconds
- No training required Platform
 - technology with multiple uses

Stand alone, non invasive, accurate, compact system with BP+Reporter




Products - Uscom SpiroSonic

Asthma, COPD, Occupational Lung Disease and drug compliance monitoring

- High fidelity digital ultrasonic spirometry
- Multi-path ultrasonic sensing
- FDA, CE, and TGA approvals
- Reliable and accurate
- Auto calibration
- Research, home and clinic
- Wireless transmission
- SpiroReporter analysis software
- FloFree tube low resistance
- Software guided examination and report
- Simple disinfection
- Platform sensors with medical and industrial applications

(10-1)



Stand alone, non invasive, accurate, compact system with SpiroReporter



Future - Big Data

Big data needs high quality sensors Uscom specialises in high quality non-invasive sensors

- Software analytics
- Telemetric signals
- Cloud based processing/diagnosis
- Personalised clinical advice
- Medication and dosage
- Serial monitoring
- Multiple measures
- Home care market
- Subscription service model
- Global partners China, US, Euro
- Multiple software providers few hardware providers















Stand alone, wireless, accurate, compact, digital devices

De-Risked Technology

Featured in 500+ peer reviewed publications and presentations





Continued Global Growth

Global

- 1. Uscom Aus
- 2. Uscom UK
- 3. Uscom Budapest
- 4. Uscom USA

Key Markets

- 1. AsiaPAC 65%
- 2/3. Europe 27%
- 4. Nth America 8%

US Focus FY 2017

Stephen Wilson – Former VP Corporate Development Welch Allyn appointed




Global Profile - Vietnam Health





China Growth



David He joins UCM Board Formerly J&J China

China Health Spend (USD)

GDP=12,000,000,000,000 Health=5.4%=648,000,000,000 Objective=12%=1,400,000,000,000 Increase=6.6%=792,000,000,000

Uscom China Targets (USD)

Population = 1.35b 3 provinces < 10% pop = \$10m 31 Provinces = 100% 10 x current UCM revenue = \$10m 2 new products = 20m Total revenue China = \$30m USD



New US Products





For launch early FY 2017



US CPT Codes


US Reimbursement Codes for Uscom Technologies

| Uscom Products | CPT Code | Descriptor | Value (USD) |
|-------------------|-------------|--------------------------------------------------------|----------------|
| BP+ | 93050 | Central BP and PWA | \$17.91 |
| SpiroSonic | 94010 | Spirometry | \$36 |
| | 94060 | Pre and post bronchodilator administration, spirometry | \$61 |
| | 94375 | Respiratory flow volume loop | \$40 |
| USCOM | 76999 | Unlisted ultrasound services - TDM* and EDM | \$76 |



Growth - UCM

A blue sky story with de-risked operations




Current revenue only from USCOM 1A BP+ and SpiroSonic revenue in FY 2017



Growth - UCM


UCM Quarterly Sales Revenue



Current revenue only from USCOM 1A BP+ and SpiroSonic revenue in FY 2017



Revenue Targets





Multi-Products

Three product ranges entering profit phase

| | Concept | Product | Pilot | Validation | Regulatory | Revenue | Global Distribution | Profit 2016 |
|------------|----------|----------|----------|------------|------------|----------|------------------------|----------------|
| USCOM 1A | ✓ | √ | 1 | √ | √ | √ | √ | ± |
| Uscom BP+ | ✓ | ✓ | √ | ✓ | √ | √ | √ | ± |
| SpiroSonic | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |

| Investment | to | Profit |
|------------|----|--------|
| | | |



The Future

Value Cascade

Products

USCOM 1A

Uscom BP+

BP+Reporter

SpiroSonic

Smart

Mobile

Tube

SpiroReporter

Sales

New appointments

Current distribution

Thor distribution

New distribution

Major partners

Re-imbursement

US market focus

Operations

Global operations

Increased products

Increased scale

Cost effective manufacture

Revenue growth

Profitability

Opportunities

Share price growth

Dividend

Transaction





Uscom

Current Objectives

- Maintain USCOM 1A 50+% growth
- Deliver BP+, BP+Reporter, SpiroSonic and SpiroReporter to market
- Complete products, regulatory and manufacturing
- Continue discussions
 - Expand distribution with high reach partners
 - Develop specific application partnerships
- Consolidate global entity and operations
- Manage rapid growth



Uscom


Operational risks

- Global medical markets unpredictable
- Product development/regulatory slower and more costly than expected
- Distribution slow to achieve revenue goals and integrate new products
- Capital for acquisitions, product development and production in advance of revenue
- Competition risks and patent breaches difficult to predict and monitor competitors
- Complexity of operating in multiple jurisdictions US, UK, Hungary, Australia
- Preserving single product revenue growth >50%
- International accounting & auditing expensive, complex and time consuming
- New product lines and new marketing time to learn
- Transitioning Budapest to volume manufacture



Right Sector - Health

ASX 10 yr CAGR % pa



UCM sales growth

2014 - 67%

2015 - 59%


- 1st Feb 2006 1st Feb 2016
- Exclusive of dividends

Healthcare, right sector.....



Right Time for Growth


Revenue Growth % pa







Industry Comparators




- Estimates *
- UCM Paterson's, ACG - Taylor Collison ADR BP - BellPotter ADR Ed - Edison

| Code | Current Cap Val | Current Price | Target | Target Cap Val |
|----------|-----------------|---------------|--------|----------------|
| UCM | 22m | 0.225 | 0.42 | 42m |
| ACG | 32m | 0.16 | 0.28 | 56m |
| ADR (BP) | 75m | 0.52 | 1.19 | 172m |
| ADR (Ed) | 75m | 0.52 | 1.31 | 189m |



ASX:UCM

Share price starting to recognise revenue growth!




Right company, right time.....



Research – UCM 2016

Fig 9: YTD Comparison Stock Sector Index







Research – UCM 2016

USCOM LIMITED

PATERSONS

Research Note

GLOBAL LAUNCH OF EXPANDED PRODUCT PORTFOLIO

Investment Highlights

5 October 2015

| 5 th Oct 2015 | 5 th Oct 2016 | 12mth Change | | |
|--------------------------|--------------------------|--------------|--|--|
| 0.14c (14m) | 0.42c (42m) | +200% | | |
| | | | | |

12 month Projections and price and cap value targets

Uscom

```
Value investment 🗸
          Strong underlying business 

            Invested in growth 

✓
          Premium global markets 🗸
      Diversified and lifesaving technologies 
       Two new product ranges for market in the next 12mths \square
       Right time − 2016 results imminent ✓
```



Uscom

"Has acquired global assets to ensure reliable revenue growth for investors for the coming decade."





Uscom (UCM) – Global Medical Devices



Thank You

Rob Phillips

PhD(med), MPhil(med), FASE, DMU(cardiol)
Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland

Executive Chairman/CEO

USCOM 1A Competitive Advantage

| Method | Manufacturer | Technology | Rel+Rep | Non- invasive | Simple | Cost | Portable | SV beat to beat |
|------------------------|--------------|-------------------|----------|------------------|----------|----------|----------|--------------------|
| USCOM 1A | Uscom | Doppler | / | / | / | ✓ | / | / |
| BioZ | Samsung | BioImpedance | × | 1 | 1 | × | 1 | X |
| NiCOM | Cheetah | BioReactance | × | 1 | 1 | × | 1 | х |
| Nexfin | Bmeye | APP | × | √ | 1 | √ | 1 | Х |
| CardioQ | Deltex | Doppler | > | × | > | × | > | × |
| LiDCO | LiDCO | LiCl dilutio +APP | √ | × | × | × | × | × |
| LiDCOrapid | LiDCO | APP | × | × | 1 | × | × | × |
| PiCCO (mod Tx + PP) | Pulsion | APP | > | X | × | × | X | X |
| FloTrac | Edwards | APP | × | × | × | × | × | X |
| PAC (Tx) | Many | Thermodilution | × | × | × | × | × | × |



Testimonials

"This machine is saving lives, there are no two ways about it."

Professor Brendan Smith, Anesthetist, Intensivist and Emergency Physician, N.S.W. Dept of Health, Australia

"USCOM has changed the way I look at the cardiovascular status of my patients. It's part of the initial shock evaluation and monitored regularly thereafter.... USCOM has now been established as the standard of care."

Dr Akash Deep, Director of Paediatric ICU, King's College Hospital, London

"The USCOM device is a simple method of accurately and noninvasively measuring central circulation, a goal of cardiology for many years. The device has the potential to change the way we approach management of sepsis, heart failure and hypertension."

Professor Malcolm West, Cardiologist, Mayne Professor of Medicine at The University of Queensland School of Medicine, Brisbane, Australia and Uscom Medical Advisory Board Member.

"I have used USCOM for over 5 years now on our very sick children, and use it to guide management. We are now beginning multi-centre, global research which will define the way USCOM is used in Paediatric Departments across the world."

Dr Joe Brierley, Consultant Intensivist, Great Ormond Street Hospital for Sick Children, London, UK.


"The USCOM device is really good; I use it in all my aneasthetics. I think there should be one on every ICU bed and on every anaesthetic patient."

Dr Steve Woodford, Consultant Anaesthetist, circulatory researcher at Australian School of Advanced Medicine, and Uscom Investor,

"To parents and doctors this machine, USCOM, is priceless. This machine is thought to have saved baby Abbie's life.

BBC Documentary "New machine helps save babies life", 2010, Nottingham Children's Hospital

BP+ Competitive Advantage













Uscom

| Uscom BP+ | TensioMed | BPLab | IEM | Centron | AtCor | | |
|----------------|-------------------------------------------------------------------|---------------------|---------------------|-------------------|-------------------|----|---------|
| Australia | Hungary | Russia | Germany | UK | Australia | | |
| USD 3,500 | USD 6,000 | USD 7,000 | USD 7,000 | USD 6,300 | USD 20,000 | | |
| 1 min | 1 min 2 min 2 | | 2 min | 1 min | 1 min | | |
| Stand-alone | ABP, needs computer | ABP, needs computer | ABP, needs computer | Stand-alone | Needs computer | | |
| CE, FDA, TGA | CE, FDA, TGA CE Aortic + brachial waveform Central systolic BP | | CE CE | CE | CE, FDA | CE | CE, FDA |
| | | | Rough waveform | Rough waveform | Rough waveform | | |
| Physical model | Statistical regression | Transfer function | Transfer function | Transfer function | Transfer function | | |



Independent research from Cambridge University, Weill Cornell, University of California, Wales Heart Institute — BP+ = Four stars

| Method of waveform recording | Device | Company | Method of calibration | Method of estimation | Clinical applicability [†] |
|---------------------------------|---------------------------------|---------------------|-------------------------|------------------------------|----------------------------------------|
| Radial tonometry | BPro ^{86,87} | HealthSTATS | Brachial-radial cuff BP | GTF (radial-aortic) | ++ |
| | SphygmoCor ^{12,88} | AtCor Medical | Brachial-radial cuff BP | (i) GTF (radial-aortic) | + |
| | | | | (ii) Late systolic shoulder | + |
| | HEM9000AI ^{39,77} | Omron | Brachial cuff BP | (i) Algorithm | ++ |
| | | | | (ii) Late systolic shoulder | ++ |
| Brachial cuff PVP | *ARCsolver ^{89,90} | | Brachial cuff BP | GTF (brachial-aortic) | +++ |
| | Centron cBP301 ^{35,91} | Centron Diagnostics | Brachial cuff BP | GTF (brachial-aortic) | ++++ |
| | Vicorder ⁹² | Skidmore Medical | Brachial cuff BP | GTF (brachial-aortic) | +++ |
| | XCEL | AtCor Medical | Brachial cuff BP | GTF (brachial-aortic) | +++ |
| | Method of Sung et al. 42 | | Brachial cuff BP | Algorithm | ++ |
| Suprasystolic | Arteriograph 37.93 | TensioMed | Brachial coff DD | Late systelic wave amplitude | |
| brachial cuff PVP | Cardioscope II ^{36,94} | Pulsecor | Brachial cuff BP | Algorithm | ++++ (E |

PVP, pulse volume plethysmography; GTF, generalized transfer function.

BP+ is on the international space station



^{*}Incorporated in Mobil-O-Graph PWA device (IEM GmbH).

[†]Personal view based on experience, operator-dependency, need for computer/software interface, with + indicating limited applicability to routine clinical practice and + + + + indicating high applicability.

SpiroSonic Competitive Advantage



















| Uscom SpiroSonic | Welch Allyn | Schiller | Sibelmed | Vitalograph | MIR | Carefusion | NDD |
|-----------------------------------------------------------------------------------------------------------|------------------------|------------------------|------------------------|------------------------|---------------------------------------------------|------------------------|--------------------------------|
| Australia | USA | Switzerland | Spain | USA | Italy | USA | Switzerland |
| SpiroSonic | SpiroPerfect | Spirovit SP-1 | Dataspir Touch | Pneumotrac | Spirodoc | Microloop | EasyOne PLus |
| USD 1,890 | USD 2,100 | USD 1,850 | USD 2,300 | USD 2,030 | USD 1,580 | USD 2,180 | USD 1,990 |
| Dual Path Ultrasound | Diff Pressure | Diff Pressure | Turbine | Diff Pressure | Turbine | Turbine | Single Path Ultrasound |
| Accurate Auto calibration SpiroReporter Fully digital FreeFlo sensor Hygeinic SpO2 Bluetooth Rechargeable | Multiple iterations | Multiple iterations | Multiple iterations | Multiple iterations | Multiple iterations Conssumable turbines | Multiple iterations | Accurate Consumable tube |